Artículos de revistas: "Primary hyperoxaluria type 1"

1

Cochat, Pierre. "Primary hyperoxaluria type 1". Kidney International 55, n.º 6 (junio de 1999): 2533–47. http://dx.doi.org/10.1046/j.1523-1755.1999.00477.x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Ajzensztejn, M. J., N. J. Sebire, R. S. Trompeter y S. D. Marks. "Primary hyperoxaluria type 1". Archives of Disease in Childhood 92, n.º 3 (1 de marzo de 2007): 197. http://dx.doi.org/10.1136/adc.2006.107334.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Abukhatwah, Mohamed W., Samia H. Almalki, Mohammed S. Althobaiti, Abdulla O. Alharbi, Najla K. Almalki y Naglaa M. Kamal. "Primary hyperoxaluria Type 1". Medicine 99, n.º 25 (19 de junio de 2020): e20371. http://dx.doi.org/10.1097/md.0000000000020371.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Kumar, Aman, Prateek Kinra y A. W. Kashif. "Autopsy Findings in an Infant with Primary Hyperoxaluria (Type-1)". Annals of Pathology and Laboratory Medicine 7, n.º 12 (30 de diciembre de 2020): C178–182. http://dx.doi.org/10.21276/apalm.2908.

Texto completo

Resumen

Histopathological findings in oxalosis patient are limited in the literature, although it has high mortality. Oxalosis, which is defined as deposition of calcium oxalate crystals in tissues, is the final stage of various hyperoxaluric syndromes. It is often missed and is rare. The diagnosis is often delayed, since it requires special laboratory tests for establishing the diagnosis. Kidneys, blood vessel walls, and bones are the major sites for crystal deposition. We present an infant autopsy case of primary hyperoxaluria, type 1. Diagnosis was established with genetic testing. On autopsy, calcium oxalate crystals which were refringent to polarized light were found in both kidneys.

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Cochat, P., A. Deloraine, M. Rotily, F. Olive, I. Liponski y N. Deries. "Epidemiology of primary hyperoxaluria type 1". Nephrology Dialysis Transplantation 10, supp8 (1 de enero de 1995): 3–7. http://dx.doi.org/10.1093/ndt/10.supp8.3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Ichiyama, Arata, Toshiaki Oda y Eiko Maeda-Nakai. "Primary Hyperoxaluria Type 1 in Japan". Cell Biochemistry and Biophysics 32, n.º 1-3 (2000): 171–76. http://dx.doi.org/10.1385/cbb:32:1-3:171.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Takayama, Tatsuya, Masao Nagata, Arata Ichiyama y Seiichiro Ozono. "Primary Hyperoxaluria Type 1 in Japan". American Journal of Nephrology 25, n.º 3 (2005): 297–302. http://dx.doi.org/10.1159/000086361.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Cochat, Pierre, Aurélia Liutkus, Sonia Fargue, Odile Basmaison, Bruno Ranchin y Marie-Odile Rolland. "Primary hyperoxaluria type 1: still challenging!" Pediatric Nephrology 21, n.º 8 (agosto de 2006): 1075–81. http://dx.doi.org/10.1007/s00467-006-0124-4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Frishberg, Yaacov, Sofia Feinstein, Choni Rinat y Alfred Drukker. "Hypothyroidism in primary hyperoxaluria type 1". Journal of Pediatrics 136, n.º 2 (febrero de 2000): 255–57. http://dx.doi.org/10.1016/s0022-3476(00)70112-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Frishberg, Yaacov, Georges Deschênes, Jaap W. Groothoff, Sally-Anne Hulton, Daniella Magen, Jérôme Harambat, William G. van’t Hoff et al. "Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1". Clinical Journal of the American Society of Nephrology 16, n.º 7 (13 de mayo de 2021): 1025–36. http://dx.doi.org/10.2215/cjn.14730920.

Texto completo

Resumen

Background and objectivesIn the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production. The objective of this first-in-human, randomized, placebo-controlled trial was to evaluate the safety, pharmacokinetic, and pharmacodynamic profiles of lumasiran in healthy participants and patients with primary hyperoxaluria type 1.Design, setting, participants, & measurementsThis phase 1/2 study was conducted in two parts. In part A, healthy adults randomized 3:1 received a single subcutaneous dose of lumasiran or placebo in ascending dose groups (0.3–6 mg/kg). In part B, patients with primary hyperoxaluria type 1 randomized 3:1 received up to three doses of lumasiran or placebo in cohorts of 1 or 3 mg/kg monthly or 3 mg/kg quarterly. Patients initially assigned to placebo crossed over to lumasiran on day 85. The primary outcome was incidence of adverse events. Secondary outcomes included pharmacokinetic and pharmacodynamic parameters, including measures of oxalate in patients with primary hyperoxaluria type 1. Data were analyzed using descriptive statistics.ResultsThirty-two healthy participants and 20 adult and pediatric patients with primary hyperoxaluria type 1 were enrolled. Lumasiran had an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment. In part A, increases in mean plasma glycolate concentration, a measure of target engagement, were observed in healthy participants. In part B, patients with primary hyperoxaluria type 1 had a mean maximal reduction from baseline of 75% across dosing cohorts in 24-hour urinary oxalate excretion. All patients achieved urinary oxalate levels ≤1.5 times the upper limit of normal.ConclusionsLumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels.Clinical Trial registry name and registration number:Study of Lumasiran in Healthy Adults and Patients with Primary Hyperoxaluria Type 1, NCT02706886

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

RINAT, CHONI, RONALD J. A. WANDERS, ALFRED DRUKKER, DAVID HALLE y YAACOV FRISHBERG. "Primary Hyperoxaluria Type I". Journal of the American Society of Nephrology 10, n.º 11 (noviembre de 1999): 2352–58. http://dx.doi.org/10.1681/asn.v10112352.

Texto completo

Resumen

Abstract. Primary hyperoxaluria type 1 is an autosomal recessive inherited metabolic disease in which excessive oxalates are formed by the liver and excreted by the kidneys, causing a wide spectrum of phenotypes ranging from renal failure in infancy to mere renal stones in late adulthood. Mutations in the AGXT gene, encoding the liver-specific enzyme alanine:glyoxylate aminotransferase, are responsible for the disease. Seven mutations were detected in eight families in Israel. Four of these mutations are novel and three occur in children living in single-clan villages. The mutations are scattered along various exons (1, 4, 5, 7, 9, 10), and on different alleles comprissing at least five different haplotypes. All but one of the mutations are in a homozygous pattern, reflecting the high rate of consanguinity in our patient population. Two affected brothers are homozygous for two different mutations expressed on the same allele. The patients comprise a distinct ethnic group (Israeli Arabs) residing in a confined geographic area. These results, which are supported by previous data, suggest for the first time that the phenomenon of multiple mutations in a relatively closed isolate is common and almost exclusive to the Israeli-Arab population. Potential mechanisms including selective advantage to heterozygotes, digenic inheritance, and the recent emergence of multiple mutations are discussed.

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Jemshad, A., CA Mansoor, DS Milliner y N. K. N. Bhushan. "Bilateral nephrocalcinosis in primary hyperoxaluria type 1". Indian Journal of Nephrology 26, n.º 5 (2016): 383. http://dx.doi.org/10.4103/0971-4065.189317.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Shah, Chintan G., Alpana J. Ohri y Amish H. Udani. "Primary Hyperoxaluria Type 1: A great masquerader". Wadia Journal of Women and Child Health 1 (1 de julio de 2022): 13–17. http://dx.doi.org/10.25259/wjwch_2022_05.

Texto completo

Resumen

Primary hyperoxaluria (PH) Types I, II, and III is an autosomal recessive inherited disorder of defect in glyoxylate metabolism due to specific hepatic enzyme deficiencies causing renal damage due to deposition of oxalate crystals that induce renal epithelial cell injury, and inflammation resulting in reduced renal oxalate elimination leading to extra renal deposition of calcium oxalate crystals. PH is under diagnosed because of phenotypic heterogeneity masquerading as infantile nephrocalcinosis (NC) with or without renal failure or renal calculus disease in adults. We present three children with genetically proven PH1 seen over last 2 years along with a brief review of the literature. In this series all cases were female. Two girls had infantile onset of symptoms and one presented in childhood. Renal failure in all with varying sonography features including small size kidneys, multiple renal calculi, bulky kidneys with loss of corticomedullary differentiation were seen. Extrarenal affection was seen in one child. Renal replacement therapy was provided in all. Awareness of PH and early diagnosis by measurement of plasma and urinary oxalate and molecular characterization helps in prompt aggressive therapy, preventing extrarenal manifestations and plan long term management.

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Nugmanova, A. M., S. A. Dikanbaeva, G. N. Chingaeva, Z. E. Zhumagulova, Eh S. Eshankulov y B. M. Auyezkhanov. "CLINICAL CASE OF PRIMARY HYPEROXALURIA TYPE 1". Pediatria. Journal named after G.N. Speransky 98, n.º 2 (10 de abril de 2019): 268–71. http://dx.doi.org/10.24110/0031-403x-2019-98-2-268-271.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Chand, Alejandro Quiroga y Frederick J. Kaskel. "Timely diagnosis of primary hyperoxaluria type 1". Nature Reviews Nephrology 5, n.º 12 (diciembre de 2009): 670–71. http://dx.doi.org/10.1038/nrneph.2009.186.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Danpure, C. J., P. R. Jennings, R. J. Penketh, P. J. Wise y C. H. Rodeck. "PRENATAL EXCLUSION OF PRIMARY HYPEROXALURIA TYPE 1". Lancet 331, n.º 8581 (febrero de 1988): 367. http://dx.doi.org/10.1016/s0140-6736(88)91171-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Cochat, Pierre, Jean Louis Faure, Priscille Divry, ChristopherJ Danpure, Bruno Descos, Catherine Wright, Philippe Takvorian y Daniel Floret. "LIVER TRANSPLANTATION IN PRIMARY HYPEROXALURIA TYPE 1". Lancet 333, n.º 8647 (mayo de 1989): 1142–43. http://dx.doi.org/10.1016/s0140-6736(89)92423-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Danpure, Christopher J. "Molecular Aetiology of Primary Hyperoxaluria Type 1". Nephron Experimental Nephrology 98, n.º 2 (17 de noviembre de 2004): e39-e44. http://dx.doi.org/10.1159/000080254.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

MUNIR, WUQAAS M., MITHLESH C. SHARMA, TINA LI, FELIPE DEALBA y DEBRA A. GOLDSTEIN. "RETINAL OXALOSIS IN PRIMARY HYPEROXALURIA TYPE 1". Retina 24, n.º 6 (diciembre de 2004): 974–76. http://dx.doi.org/10.1097/00006982-200412000-00024.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Small, Kent W. "Enzyme Deficiency for Type 1 Primary Hyperoxaluria". Archives of Ophthalmology 110, n.º 1 (1 de enero de 1992): 13. http://dx.doi.org/10.1001/archopht.1992.01080130015005.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Eam, Euhun, Joshua Chang, Katreya Lovrenert, Michelle Baum, Friedhelm Hildebrandt, Donald Bodner, Fredrick Schumacher y Chen-han Wu. "GENETIC PREVALENCE OF PRIMARY HYPEROXALURIA TYPE 1". Molecular Genetics and Metabolism 138, n.º 3 (marzo de 2023): 107408. http://dx.doi.org/10.1016/j.ymgme.2023.107408.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Imtinene, Ben Mrad, Kamoun Sofien, Ben Mrad Melek, Zairi Ihsen, Oumaya Zeineb, Ben Fatma Lilia, Mami Ikram, Kaaroud Hayet, Khadija Mzoughi y Kraiem Sondos. "Case Report: Syncopal atrioventricular block complicating primary hyperoxaluria type 1". F1000Research 10 (10 de septiembre de 2021): 914. http://dx.doi.org/10.12688/f1000research.54890.1.

Texto completo

Resumen

Primary hyperoxaluria (PH) type 1 is a rare hereditary metabolic disorder resulting in accumulation of calcium oxalate in several organs, including the heart. Cardiac oxalosis in PH is poorly described in the medical literature. We report the case of a 42-year-old woman diagnosed with primary hyperoxaluria type 1 and end-stage renal failure who presented with syncope related to a paroxysmal third-degree atrioventricular block. The patient benefited from the implantation of a dual chamber pacemaker with a good outcome. Conduction blocks in case of primary hyperoxaluria type 1 are exceptional; in fact, less than five reports have previously been published in the medical literature. With this case, we would like to highlight the need for regular and careful monitoring of cardiac status in patients treated for primary oxalosis, especially when renal function is impaired.

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Harambat, Jérôme, Sonia Fargue, Justine Bacchetta, Cécile Acquaviva y Pierre Cochat. "Primary Hyperoxaluria". International Journal of Nephrology 2011 (2011): 1–11. http://dx.doi.org/10.4061/2011/864580.

Texto completo

Resumen

Primary hyperoxalurias (PH) are inborn errors in the metabolism of glyoxylate and oxalate. PH type 1, the most common form, is an autosomal recessive disorder caused by a deficiency of the liver-specific enzyme alanine, glyoxylate aminotransferase (AGT) resulting in overproduction and excessive urinary excretion of oxalate. Recurrent urolithiasis and nephrocalcinosis are the hallmarks of the disease. As glomerular filtration rate decreases due to progressive renal damage, oxalate accumulates leading to systemic oxalosis. Diagnosis is often delayed and is based on clinical and sonographic findings, urinary oxalate assessment, DNA analysis, and, if necessary, direct AGT activity measurement in liver biopsy tissue. Early initiation of conservative treatment, including high fluid intake, inhibitors of calcium oxalate crystallization, and pyridoxine in responsive cases, can help to maintain renal function in compliant subjects. In end-stage renal disease patients, the best outcomes have been achieved with combined liver-kidney transplantation which corrects the enzyme defect.

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Rumsby, G., T. Weir y C. T. Samuell. "A Semiautomated Alanine: Glyoxylate Aminotransferase Assay for the Tissue Diagnosis of Primary Hyperoxaluria Type 1". Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 34, n.º 4 (julio de 1997): 400–404. http://dx.doi.org/10.1177/000456329703400411.

Texto completo

Resumen

We have developed a sensitive assay for the measurement of alanine:glyoxylate aminotransferase (EC 2.6.1.44) activity in human liver. The assay is partly automated, and takes into consideration the sensitivity of the reaction to pH and to glyoxylate concentration. It is less subject to interference from other enzymes utilizing glyoxylate and to chemical interference from glyoxylate itself and can therefore be used without correction for cross-over by glutamate:glyoxylate aminotransferase (EC 2.6.1.4). The assay allows clear discrimination between normal and affected livers and is sufficiently sensitive to measure enzyme activity in fetal liver samples. Enzyme activity ranged from 17·9 to 38·5 μmol/h/mg protein in control livers ( n = 9) and 0·8 to 9·5 μmol/h/mg protein in 30 of 39 hyperoxaluric patients studied. Normal alanine: glyoxylate aminotransferase activity (from 22·8 to 45·5 μmol/h/mg protein) allowed exclusion of primary hyperoxaluria type 1 in the other nine hyperoxaluric patients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Edwards, P. y G. A. Rose. "Metabolism of Pyridoxine in Mild Metabolic Hyperoxaluria and Primary Hyperoxaluria (Type 1)". Urologia Internationalis 47, n.º 3 (1991): 113–17. http://dx.doi.org/10.1159/000282203.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Waddell, Benjamin y Daniel McKenney. "Type 1 primary hyperoxaluria in a male infant". Kidney Research and Clinical Practice 36, n.º 4 (31 de diciembre de 2017): 393. http://dx.doi.org/10.23876/j.krcp.2017.36.4.393.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Cochat, Pierre, Sonia Fargue y Jérôme Harambat. "Primary hyperoxaluria type 1: strategy for organ transplantation". Current Opinion in Organ Transplantation 15, n.º 5 (octubre de 2010): 590–93. http://dx.doi.org/10.1097/mot.0b013e32833e35f5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Allen, A. R., E. M. Thompson, G. Williams, R. W. E. Watts y C. D. Pusey. "Selective renal transplantation in primary hyperoxaluria type 1". American Journal of Kidney Diseases 27, n.º 6 (junio de 1996): 891–95. http://dx.doi.org/10.1016/s0272-6386(96)90529-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Cochat, Pierre y Jaap Groothoff. "Primary hyperoxaluria type 1: practical and ethical issues". Pediatric Nephrology 28, n.º 12 (14 de marzo de 2013): 2273–81. http://dx.doi.org/10.1007/s00467-013-2444-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Danpure, C. J., P. R. Jennings, P. Fryer, P. E. Purdue y J. Allsop. "Primary hyperoxaluria type 1: Genotypic and phenotypic heterogeneity". Journal of Inherited Metabolic Disease 17, n.º 4 (1994): 487–99. http://dx.doi.org/10.1007/bf00711363.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Sakamoto, Taiji. "Enzyme Deficiency for Type 1 Primary Hyperoxaluria-Reply". Archives of Ophthalmology 110, n.º 1 (1 de enero de 1992): 13. http://dx.doi.org/10.1001/archopht.1992.01080130015006.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Birtel, Johannes, Philipp Herrmann, Sander F. Garrelfs, Simon Dulz, Yevgeniya Atiskova, Roselie M. Diederen, Martin Gliem et al. "The Ocular Phenotype in Primary Hyperoxaluria Type 1". American Journal of Ophthalmology 206 (octubre de 2019): 184–91. http://dx.doi.org/10.1016/j.ajo.2019.04.036.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Sethi, Sidharth Kumar, Hans R. Waterham, Sonika Sharma, Alok Sharma, Pankaj Hari y Arvind Bagga. "Primary hyperoxaluria type 1 with a novel mutation". Indian Journal of Pediatrics 76, n.º 2 (22 de septiembre de 2008): 215–17. http://dx.doi.org/10.1007/s12098-008-0187-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Leumann, Ernst y Bernd Hoppe. "Primary hyperoxaluria type 1: is genotyping clinically helpful?" Pediatric Nephrology 20, n.º 5 (17 de marzo de 2005): 555–57. http://dx.doi.org/10.1007/s00467-005-1813-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

El Hage, Samer, Ismat Ghanem, André Baradhi, Chebel Mourani, Samir Mallat, Fernand Dagher y Khalil Kharrat. "Skeletal features of primary hyperoxaluria type 1, revisited". Journal of Children's Orthopaedics 2, n.º 3 (junio de 2008): 205–10. http://dx.doi.org/10.1007/s11832-008-0082-4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

BAIKO, S. V. "Primary hyperoxaluria: diagnostics, treatment, outcomes". Practical medicine 18, n.º 6 (2020): 49–57. http://dx.doi.org/10.32000/2072-1757-2020-6-49-57.

Texto completo

Resumen

Primary hyperoxaluria (PH) is a rare autosomal recessive disease caused by defects in liver glyoxylate metabolism and leading to overproduction of oxalates. Of the three types of PH, type I is the most common and severe form of the disease, which is caused by deficiency or loss of the liver-specific, vitamin B6-dependent, peroxisomal enzyme alanine-glyoxylateaminotransferase (AGT). In all types of PH, urinary excretion of oxalate is strongly elevated (> 1 mmol /1,73 m2/24 h), which results in recurrent urolithiasis and/or progressive nephrocalcinosis and subsequently, with a decrease in glomerular filtration rate (GFR), to the deposition of oxalates in the tissues of the body and the development of systemic oxalosis. PH type I is diagnosed late, in > 30% of patients already at the terminal stage of renal disease (ESRD). Every fourth patient with PH type II achieves ESRD, but cases of ESRD in type III are extremely rare. The diagnosis of PH is based on clinical and imaging (ultrasound, X-ray, CT scan) findings, urine oxalate assessment, genetic analysis. Early initiation of conservative treatment (high fluid intake, sodium citrate, etc.) is aimed at preserving renal function. Pyridoxine treatment can be effective in about 30% of patients with PH type I. Time on dialysis in anticipation of transplantation should be short to avoid overt systemic oxalosis. Transplantation methods depend on the type of PH and on the degree of GFR reduction, but combined liver and kidney transplantation is the method of choice in patients with primary hyperoxaluria type I. High index of clinical suspicion of PH must be in patients with nephrocalcinosis and/or recurrent urolithiasis, especially if urinary stones are predominantly whewellite (calcium oxalate monohydrate) in order to start early conservative treatment and preserve kidney function.

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Milliner, Dawn S., Tracy L. McGregor, Aliza Thompson, Bastian Dehmel, John Knight, Ralf Rosskamp, Melanie Blank et al. "End Points for Clinical Trials in Primary Hyperoxaluria". Clinical Journal of the American Society of Nephrology 15, n.º 7 (12 de marzo de 2020): 1056–65. http://dx.doi.org/10.2215/cjn.13821119.

Texto completo

Resumen

Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in partnership with the Oxalosis and Hyperoxaluria Foundation, initiated a project to identify end points for clinical trials. A workgroup of physicians, scientists, patients with primary hyperoxaluria, industry, and United States regulators critically examined the published literature for clinical outcomes and potential surrogate end points that could be used to evaluate new treatments. Kidney stones, change in eGFR, urine oxalate, and plasma oxalate were the strongest candidate end points. Kidney stones affect how patients with primary hyperoxaluria feel and function, but standards for measurement and monitoring are lacking. Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable. Epidemiologic data show a strong relationship between urine oxalate and long-term kidney function loss. Urine oxalate is reasonably likely to predict clinical benefit, due to its causal role in stone formation and kidney damage in CKD stages 1–3a, and plasma oxalate is likely associated with risk of systemic oxalosis in CKD 3b–5. Change in slope of eGFR could be considered the equivalent of a clinically meaningful end point in support of traditional approval. A substantial change in urine oxalate as a surrogate end point could support traditional approval in patients with primary hyperoxaluria type 1 and CKD stages 1–3a. A substantial change in markedly elevated plasma oxalate could support accelerated approval in patients with primary hyperoxaluria and CKD stages 3b–5. Primary hyperoxaluria type 1 accounts for the preponderance of available data, thus heavily influences the conclusions. Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

Garrelfs, Sander F., Yaacov Frishberg, Sally A. Hulton, Michael J. Koren, William D. O’Riordan, Pierre Cochat, Georges Deschênes et al. "Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1". New England Journal of Medicine 384, n.º 13 (1 de abril de 2021): 1216–26. http://dx.doi.org/10.1056/nejmoa2021712.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Diallo, Ousséini, Françoise Janssens, Michelle Hall y E. Fred Avni. "Type 1 Primary Hyperoxaluria in Pediatric Patients:Renal Sonographic Patterns". American Journal of Roentgenology 183, n.º 6 (diciembre de 2004): 1767–70. http://dx.doi.org/10.2214/ajr.183.6.01831767.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Garrelfs, Sander F., Dewi van Harskamp, Hessel Peters-Sengers, Chris H. P. van den Akker, Ronald J. A. Wanders, Frits A. Wijburg, Johannes B. van Goudoever, Jaap W. Groothoff, Henk Schierbeek y Michiel J. S. Oosterveld. "Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients". Journal of the American Society of Nephrology 32, n.º 12 (22 de octubre de 2021): 3175–86. http://dx.doi.org/10.1681/asn.2021060729.

Texto completo

Resumen

BackgroundPrimary hyperoxaluria type 1 (PH1) is an inborn error of glyoxylate metabolism, characterized by increased endogenous oxalate production. The metabolic pathways underlying oxalate synthesis have not been fully elucidated, and upcoming therapies require more reliable outcome parameters than the currently used plasma oxalate levels and urinary oxalate excretion rates. We therefore developed a stable isotope infusion protocol to assess endogenous oxalate synthesis rate and the contribution of glycolate to both oxalate and glycine synthesis in vivo.MethodsEight healthy volunteers and eight patients with PH1 (stratified by pyridoxine responsiveness) underwent a combined primed continuous infusion of intravenous [1-13C]glycolate, [U-13C2]oxalate, and, in a subgroup, [D5]glycine. Isotopic enrichment of 13C-labeled oxalate and glycolate were measured using a new gas chromatography–tandem mass spectrometry (GC-MS/MS) method. Stable isotope dilution and incorporation calculations quantified rates of appearance and synthetic rates, respectively.ResultsTotal daily oxalate rates of appearance (mean [SD]) were 2.71 (0.54), 1.46 (0.23), and 0.79 (0.15) mmol/d in patients who were pyridoxine unresponsive, patients who were pyridoxine responsive, and controls, respectively (P=0.002). Mean (SD) contribution of glycolate to oxalate production was 47.3% (12.8) in patients and 1.3% (0.7) in controls. Using the incorporation of [1-13C]glycolate tracer in glycine revealed significant conversion of glycolate into glycine in pyridoxine responsive, but not in patients with PH1 who were pyridoxine unresponsive.ConclusionsThis stable isotope infusion protocol could evaluate efficacy of new therapies, investigate pyridoxine responsiveness, and serve as a tool to further explore glyoxylate metabolism in humans.

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Jamieson, Neville V. y Katharine A. Jamieson. "Primary Hyperoxaluria Type 1: Gene Therapy by Liver Transplantation". Transplantation 87, n.º 9 (mayo de 2009): 1273–74. http://dx.doi.org/10.1097/tp.0b013e3181a17157.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Toussaint, Charles, Anne Vienne, Luc De Pauw, Michel Gelin, Françoise Janssen, Michele Hall, Thierry Schurmans y Jean-Lambert Pasteels. "COMBINED LIVER-KIDNEY TRANSPLANTATION IN PRIMARY HYPEROXALURIA TYPE 1". Transplantation 59, n.º 12 (junio de 1995): 1700–1704. http://dx.doi.org/10.1097/00007890-199506270-00010.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Poloni, José Antonio T., Clotilde D. Garcia, Liane N. Rotta y Mark A. Perazella. "Calcium oxalate crystalluria points to primary hyperoxaluria type 1". Kidney International 89, n.º 1 (enero de 2016): 250. http://dx.doi.org/10.1016/j.kint.2015.11.001.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Danpure, Christopher J. "Molecular and Clinical Heterogeneity in Primary Hyperoxaluria Type 1". American Journal of Kidney Diseases 17, n.º 4 (abril de 1991): 366–69. http://dx.doi.org/10.1016/s0272-6386(12)80624-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Burns, Nadja, Brian Castillo, Aditya Gupta, Brandy McKelvy y Sozos Papasozomenos. "Primary Hyperoxaluria Type 1 With Systemic Calcium Oxalate Deposition". American Journal of Clinical Pathology 138, suppl 1 (1 de julio de 2012): A002. http://dx.doi.org/10.1093/ajcp/138.suppl1.002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Kemper, M. J., M. Burdelski y D. E. Müller‐Wiefel. "Combined liver‐kidney transplantation for primary hyperoxaluria type 1". Nephrology Dialysis Transplantation 16, n.º 10 (1 de octubre de 2001): 2113–14. http://dx.doi.org/10.1093/ndt/16.10.2113.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Cochat, P., J. M. Gaulier, P. C. Koch Nogueira, J. Feber, N. V. Jamieson, M. O. Rolland, P. Divry, D. Bozon y L. Dubourg. "Combined liver-kidney transplantation in primary hyperoxaluria type 1". European Journal of Pediatrics 158, S2 (1 de enero de 1999): S075—S080. http://dx.doi.org/10.1007/pl00014327.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Toussaint, C., L. De Pauw, C. Tielemans y D. Abramowicz. "Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1". Nephrology Dialysis Transplantation 10, supp8 (1 de enero de 1995): 17–21. http://dx.doi.org/10.1093/ndt/10.supp8.17.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Brooks, Ellen R., Bernd Hoppe, Dawn S. Milliner, Eduardo Salido, John Rim, Leah M. Krevitt, Julie B. Olson, Heather E. Price, Gulsah Vural y Craig B. Langman. "Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria". American Journal of Nephrology 43, n.º 4 (2016): 293–303. http://dx.doi.org/10.1159/000445448.

Texto completo

Resumen

Background: Primary hyperoxaluria type 1 (PH1) and idiopathic hypercalciuria (IHC) are stone-forming diseases that may result in the formation of calcium (Ca) oxalate (Ox) stones, nephrocalcinosis, and progressive chronic kidney disease (CKD). Poorer clinical outcome in PH1 is segregated by the highest urine (Ur)-Ox (UrOx), while IHC outcomes are not predictable by UrCa. We hypothesized that differences would be found in selected Ur-protein (PRO) patterns in PH1 and IHC, compared to healthy intra-familial sibling controls (C) of PH1 patients. We also hypothesized that the PRO patterns associated with higher UrOx levels would reflect injury, inflammation, biomineralization, and abnormal tissue repair processes in PH1. Methods: Twenty four-hour Ur samples were obtained from 3 cohorts: PH1 (n = 47); IHC (n = 35) and C (n = 13) and were analyzed using targeted platform-based multi-analyte profile immunoassays and for UrOx and UrCa by biochemical measurements. Results: Known stone matrix constituents, osteopontin, calbindin, and vitronectin were lowest in PH1 (C > IHC > PH1; p < 0.05). Ur-interleukin-10; chromogranin A; epidermal growth factor (EGF); insulin-like growth factor-1 (IGF-1), and macrophage inflammatory PRO-1α (MIP-1α) were higher in PH1 > C (p = 0.03 to p < 0.05). Fetuin A; IGF-1, MIP-1α, and vascular cell adhesion molecule-1 were highest in PH1 > IHC (p < 0.001 to p = 0.005). Conclusion: PH1 Ur-PROs reflected overt inflammation, chemotaxis, oxidative stress, growth factors (including EGF), and pro-angiogenic and calcification regulation/inhibition compared to the C and IHC cohorts. Many of the up- and downregulated PH1-PROs found in this study are also found in CKD, acute kidney injury, stone formers, and/or stone matrices. Further data analyses may provide evidence for PH1 unique PROs or demonstrate a poorer clinical outcome.

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Blaschke, Sabine, Clemens Grupp, Jens Haase, Thomas Kleinoeder, Christian Hallermann, Ilka Troche, Hermann-J. Gröne y Gerhard A. Müller. "A case of late-onset primary hyperoxaluria type 1". American Journal of Kidney Diseases 39, n.º 2 (febrero de 2002): e11.1. http://dx.doi.org/10.1053/ajkd.2002.30586.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Artículos de revistas sobre el tema "Primary hyperoxaluria type 1"

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros